Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
3(75.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04608812Phase 1Terminated

Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection

Role: collaborator

NCT02500459Early Phase 1Terminated

Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

Role: collaborator

NCT03193463Early Phase 1Withdrawn

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

Role: collaborator

NCT02278510Early Phase 1Completed

Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma

Role: collaborator

All 4 trials loaded